Deirdre Connelly
Deirdre Connelly is president, North America Pharmaceuticals for GlaxoSmithKline (GSK). The global health care company announced on July 25 that Health Canada had approved a BRAF-inhibitor, Tafinlar, and MEK-inhibitor, Mekinist, for melanoma patients with BRAF V600 mutation, offering new hope for those afflicted with metastatic melanoma. Deirdre is a member of the global Corporate ExecutiveRead more..